[Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

19:55 EST 5 Mar 2014 | The Lancet

Increased clinical disease activity associated with atacicept suggests that the role of B cells and humoral immunity in multiple sclerosis is complex. For studies that explore therapeutic immunomodulation in multiple sclerosis, rigorous monitoring fo...

Original Article: [Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial"

Search BioPortfolio:
Advertisement

Relevant Topics

Immunology
Latest News Clinical Trials Research Drugs Reports Corporate
Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand and prevent autoimmune condtions, cancers of immune cells and immune deficiencies. Immunotherapy i...

Neurology - Central Nervous System (CNS)
Latest News Clinical Trials Research Drugs Reports Corporate
Neurology is the branch of medicine concerned with nerves; both the central nervous system and the peripheral nervous system. This includes strokes and disorders affecting the brain aswell as spinal cord damage and peripheral neuropathies.The complexity ...

Advertisement

Searches Linking to this Story